Biofrontera

BFRI56

Penny Stock

$0.87arrow_drop_up56.78%$0.43

Penny Stock

BFRI56

$0.87

arrow_drop_up56.78%$0.43

Penny Stock

Performance History

Key Stats
Open	$0.79
Prev. Close	$0.75
EPS	1.16
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$6.74M

	LOW	HIGH
Day Range	0.74	1.27
52 Week Range	0.61	8.99

Ratios

Revenue	-





EPS	1.16

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Biofrontera (BFRI)

Biofrontera Inc. (BFRI) is a pharmaceutical company focused on the development and commercialization of dermatological drugs for the treatment of skin diseases. The company's lead product is Ameluz, a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK), a precancerous condition of the skin. Ameluz is a gel formulation containing the active ingredient aminolevulinic acid (ALA), which is applied to the affected area of the skin and activated by light therapy. The company also markets a portable light source device called BF-RhodoLED for use in conjunction with Ameluz.

Biofrontera Inc. was founded in 1997 and is headquartered in Leverkusen, Germany. The company's stock, ticker symbol BFRI, is listed on the Nasdaq exchange. The stock price history of Biofrontera Inc. shows fluctuations over time, influenced by factors such as clinical trial results, regulatory approvals, and market conditions. Investors can track the stock price of BFRI using financial websites or trading platforms. It is important to note that stock prices can be volatile and may be subject to sudden changes based on market events.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Dr. Hermann Luebbert Ph.D.
Headquarters: Woburn
Employees: 81
Exchange: NASDAQ

Keep an eye on Biofrontera

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Biofrontera's (BFRI) price per share?

The current price per share for Biofrontera (BFRI) is $0.87. The stock has seen a price change of $0.43 recently, indicating a 56.79% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Biofrontera (BFRI)?

For Biofrontera (BFRI), the 52-week high is $8.99, which is 933.33% from the current price. The 52-week low is $0.61, the current price is 42.62% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Biofrontera (BFRI) a growth stock?

Biofrontera (BFRI) has shown an average price growth of -4.13% over the past three years. It has received a score of -3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Biofrontera as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Biofrontera (BFRI) stock price performance year to date (YTD)?

As of the latest data, Biofrontera (BFRI) has a year-to-date price change of -68.93%. Over the past month, the stock has experienced a price change of -9.84%. Over the last three months, the change has been -26.27%. Over the past six months, the figure is -17.92%.

help

Is Biofrontera (BFRI) a profitable company?

Biofrontera (BFRI) has a net income of -$20.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 48.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -64.69% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 18.82%, providing insight into the company's sales performance and growth. The gross profit is $16.63M. Operating income is noted at -$22.68M. Furthermore, the EBITDA is -$18.32M.

help

What is the market capitalization of Biofrontera (BFRI)?

Biofrontera (BFRI) has a market capitalization of $6.74M. The average daily trading volume is 1.14, indicating the stock's liquidity and investor engagement.